Scientifically formulated nutraceutical products designed to support immune health and prevent microbial infections.
NUTRACEUTICS
In the pharmaceutical industry, it is mandatory to do clinical tests on animals or in vitro for the verification of a compound’s effects. On the contrary, in nutrition, there was no such method in the past for the verification of effects of foods in preventing or treating diseases. In recent years, however, the food composition has bIn the pharmaceutical industry, it is mandatory to do clinical tests on animals or in vitro for the verification of a compound’s effects. On the contrary, in nutrition, there was no such method in the past for the verification of effects of foods in preventing or treating diseases. In recent years, however, the food composition has been scientifically tested and verified as people are becoming more and more aware of health-related issues and how food can directly or indirectly be responsible for maintaining proper health and preventing diseases. This approach is followed by Elysium Cell B io ITA. Each nutraceutical product designed is subjected to a clinical trial to demonstrate its safety and efficacy.een scientifically tested and verified as people are becoming more and more aware of health-related issues and how food can directly or indirectly be responsible for maintaining proper health and preventing diseases. This approach is followed by Elysium Cell B io ITA. Each nutraceutical product designed is subjected to a clinical trial to demonstrate its safety and efficacy.
Development of Elysium "Nose-Throat" Nano-spray and Elysium Nose Throat PLUS ipertonic solution for KIDS.
Elysium Cell Bio ITA has developed a novel “DIETARY SUPPLEMENT” Elysium Nose-Throat is a dietary supplement based on Mullein, Thyme, Propolis and Polyphosphates. The product is registered “AS FOOD SUPPLEMENTS” at the MINISTRY OF HEALTH code NO. 163054. The product is Patented by Elysium Cell bio ITA srl 80145 – Naples (n. 102023000016338, August 2023; n. 102024000005170, March 2024 and EU patent application, European Patent EP24192124 31/07/2024 “Composition with antiviral, antibacterial and antifungal activity” ).
Article published 17-06-24 on Journal Translational Medicine (BMC- Nature publishing Group).
Pricing
New clients – еnjoy a $50 discount on any session below!
Package
Save with our discounted packages for multiple sessions.
Development of Elysium " Natural SKIN care - FACE and BODY CREAM
- Chronic muscle stiffness
- Headaches
- Carpal Tunnel
- Postural imbalances
Development of Immune MAX Biotics
A new formula containing Bromelin, Hyppocastan , Boswellia, Quercetin, Uncaria, Vitamine C, Propolis, Verbascum and Timus Vulgaris to figth inflammations and systemic infections and enhance the innate immune response,
This product is now ready for the market and on sales by the 1st of December 2024. The benefits are described PRUDUCTS website section
Development of Neuromentis Q10
a new formula that lies in the development of metabolic energy for neuronal functioning, neural protection, and as a powerful antioxidant. These functions are enhanced to improve memory and learning. Suitable during stressful periods to reduce anxiety and enhance concentration in daily activities that require high attention and memory. Neuromentis Q10 is a dietary supplement formulated with Coenzyme Q10, Citicoline, Ginkgo Biloba, Quercetin, Astaxanthin, vitamins, and minerals that act synergistically to support brain wellness. The benefits are described PRUDUCTS website section
CANCER
Elysium Cell Bio ITA is focused on translational studies (in vitro and in vivo) on metastatic brain tumors and breast cancers (e.g., Medulloblastoma and Triple Negative Breast Cancer, respectively) by studying those changes occurring within the tumor microenvironment affecting the cellular metabolism due to the application of new small molecules able to inhibit the Warburg effect and enhance the immunotherapeutic benefits.
Therapeutics
Elysium Cell Bio ITA has developed non toxic molecules capable to target Prune1 in tumorigenic cells by enhancing its intracellular degradation, thus inhibiting its related metastatic axis, by reducing TGF-beta signalling in the tumor microenvironment and affecting the epithelial to mesenchymal transition.
Patent related to this project: European Patent 28/10/2022 n. EP22204452, “Prune1 inhibitors Iand therapeutics use thereof ”.
References related to this issue:
https://pubmed.ncbi.nlm.nih.gov/29490009/; https://www.sciencedirect.com/science/article/pii/S2589004220311354